Payers' views of the changes arising through the possible adoption of Adaptive Pathways

• Main Authors: Michael Ermisch (Author), Anna Bucsics (Author), Patricia Vella Bonanno (Author), Francis Arickx (Author), Alexander Bybau (Author), Tomasz Bochenek (Author), Marc Van De Casteele (Author), Eduardo Diogene (Author), Jurij Furst (Author), Kristina Garuoliene (Author), Martin van der Graaff (Author), Jolanta Gulbinovic (Author), Alan Haycox (Author), Jan Jones (Author), Roberta Joppi (Author), Ott Laius (Author), Irene Langner (Author), Anthony Martin (Author), Vanda Markovic-Pekovic (Author), Laura McCullagh (Author), Einar Magnusson (Author), Ellen Nilsen (Author), Gisbert Selke (Author), Catherine Sermet (Author), Steven Simoens (Author), Robert Sauermann (Author), Ad Schuurman (Author), Ricardo Ramos (Author), Vera Vlahovic-Palcevski (Author), Corinne Zara (Author), Brian Godman (Author)
• Format: Knjiga
• Izdano: Frontiers Media S.A., 2016-09-01T00:00:00Z.
• Teme: article
• Online dostop: Connect to this object online.

Payers are a major stakeholder in any considerations and initiatives concerning adaptive licensing of new medicinal products, also referred to as Medicines Adaptive Pathways to patients (MAPPs). Firstly, the scope and necessity of MAPPs need further scrutiny, especially with regard to the definition...